2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
186
HER2-positive Breast Cancer
18
Neoplasms
13
Neoplasm Metastasis
11
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Drug Therapy
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Mitomycin
3
Docetaxel
3
Cetuximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
pertuzumab
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled